[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2508290T3 - Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo - Google Patents

Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo Download PDF

Info

Publication number
ES2508290T3
ES2508290T3 ES10749258.9T ES10749258T ES2508290T3 ES 2508290 T3 ES2508290 T3 ES 2508290T3 ES 10749258 T ES10749258 T ES 10749258T ES 2508290 T3 ES2508290 T3 ES 2508290T3
Authority
ES
Spain
Prior art keywords
rtki
administration
eye
pharmaceutical composition
tyrosine kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10749258.9T
Other languages
English (en)
Inventor
Bhagwati P. Kabra
Malay Ghosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Research LLC filed Critical Alcon Research LLC
Application granted granted Critical
Publication of ES2508290T3 publication Critical patent/ES2508290T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disolución acuosa para tratar neovascularización ocular, comprendiendo dicha composicion: un principio activo escasamente soluble en agua en una cantidad de desde el 0,01% hasta el 5%, agua y un polietilenglicol que tiene un peso molecular de al menos 4000 en una cantidad de desde el 25% hasta el 50%; en la que la composición es una composición acuosa preparada para inyección intravitrea.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
    imagen2
ES10749258.9T 2009-03-03 2010-03-03 Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo Active ES2508290T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US156922P 1999-09-28
US15692209P 2009-03-03 2009-03-03
PCT/US2010/026033 WO2010101992A1 (en) 2009-03-03 2010-03-03 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Publications (1)

Publication Number Publication Date
ES2508290T3 true ES2508290T3 (es) 2014-10-16

Family

ID=42678800

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10749258.9T Active ES2508290T3 (es) 2009-03-03 2010-03-03 Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo

Country Status (12)

Country Link
US (2) US20100227905A1 (es)
EP (1) EP2403335B1 (es)
JP (1) JP5583146B2 (es)
KR (2) KR20160135372A (es)
CN (1) CN102340991B (es)
AU (1) AU2010221369B2 (es)
BR (1) BRPI1012302A2 (es)
CA (1) CA2753690A1 (es)
ES (1) ES2508290T3 (es)
MX (1) MX2011008731A (es)
WO (1) WO2010101992A1 (es)
ZA (1) ZA201105505B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110122881A (ko) 2006-04-07 2011-11-11 워너 칠콧 컴퍼니 엘엘씨 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
KR101426125B1 (ko) 2009-07-06 2014-08-06 에르피오 세러퓨틱스 인코포레이티드 암 세포의 전이 예방을 위한 화합물, 조성물 및 방법
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
JP2013535451A (ja) * 2010-07-21 2013-09-12 アルコン リサーチ， リミテッド 増強された溶解度特徴を有する薬学的組成物
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US20140160236A1 (en) * 2011-07-29 2014-06-12 The Regents Of The University Of California Lensfree holographic microscopy using wetting films
EP2766043A4 (en) 2011-10-13 2015-06-10 Aerpio Therapeutics Inc METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER
AU2013209452B2 (en) 2012-01-19 2015-11-05 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
EP2825206A1 (en) 2012-03-16 2015-01-21 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
EP3808339A1 (en) 2012-05-03 2021-04-21 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2871778C (en) 2012-05-03 2022-09-13 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6392209B2 (ja) 2012-05-04 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9914770B2 (en) * 2013-04-30 2018-03-13 Intas Pharmaceuticals Ltd Cloning, expression and purification method for the preparation of ranibizumab
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
AU2015362621B2 (en) 2014-12-15 2019-01-17 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of ocular disorders
WO2016123125A1 (en) 2015-01-27 2016-08-04 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
ES2894802T3 (es) 2015-09-23 2022-02-15 Aerpio Pharmaceuticals Inc Activadores de Tie-2 para su uso en el tratamiento de la presión intraocular
KR20180102069A (ko) 2015-11-12 2018-09-14 그레이버그 비젼, 인크. 요법을 위한 응집성 마이크로입자
WO2018175922A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
JP2020519585A (ja) 2017-05-10 2020-07-02 グレイバグ ビジョン インコーポレイテッド 医学療法のための延長放出マイクロ粒子及びその懸濁液
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE-2 ACTIVATORS TARGETING THE SCHLEMM CHANNEL
EP4065131B1 (en) * 2019-11-28 2024-09-18 Caprika Srl Rectal-use composition for the treatment of constipation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
DK0694310T3 (da) * 1993-04-16 2000-06-05 Wakamoto Pharma Co Ltd Reversibelt, termisk gelatinerende, vandbaseret, medicinsk præparat
AU734650B2 (en) * 1996-05-07 2001-06-21 Toray Industries, Inc. Ophthalmic preparations
SI1638941T1 (sl) * 2003-05-22 2010-11-30 Abbott Lab Inhibitorji indazol benzizoksazol in benzizotiazol kinaze
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN101006988A (zh) * 2005-09-26 2007-08-01 刘凤鸣 葛根素的缓释制剂
EP1962803A1 (en) * 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2007076454A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
CN101687042A (zh) * 2007-07-20 2010-03-31 爱尔康公司 用于递送作为受体酪氨酸激酶抑制剂(RTKi)的化合物至眼部的药物制剂

Also Published As

Publication number Publication date
US20130137741A1 (en) 2013-05-30
KR20110130454A (ko) 2011-12-05
CN102340991A (zh) 2012-02-01
US20100227905A1 (en) 2010-09-09
AU2010221369B2 (en) 2014-03-13
EP2403335B1 (en) 2014-08-20
KR20160135372A (ko) 2016-11-25
EP2403335A4 (en) 2012-08-29
EP2403335A1 (en) 2012-01-11
JP2012519694A (ja) 2012-08-30
BRPI1012302A2 (pt) 2015-09-22
WO2010101992A1 (en) 2010-09-10
AU2010221369A1 (en) 2011-08-25
CN102340991B (zh) 2014-02-26
MX2011008731A (es) 2011-09-29
CA2753690A1 (en) 2010-09-10
ZA201105505B (en) 2013-10-30
JP5583146B2 (ja) 2014-09-03

Similar Documents

Publication Publication Date Title
ES2508290T3 (es) Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
CL2019003433A1 (es) Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de receptor tirosina quinasa (rtk), o un inhibidor de la angiogénesis, y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014).
ES2601127T3 (es) Derivado de pirazol y su uso con fines médicos
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
AR058620A1 (es) Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
AR052198A1 (es) Formulaciones anticuerpo anti a beta
AR077338A1 (es) Formulacion farmaceutica. procedimiento de preparacion. disolucion para perfusion.
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
PE20141585A1 (es) Composicion farmaceutica estabilizada a base de un compuesto no petidico
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
CL2013003163A1 (es) Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.
AR058619A1 (es) Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
IN2013MN02384A (es)
CO6351721A2 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
UY31768A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
UY31343A1 (es) Composicion con una combinacion de principios activos para el tratamiento del estrenimiento